Nothing Special   »   [go: up one dir, main page]

MA34130B1 - SOLID PHARMACEUTICAL FORMULATIONS OF RAMIPRIL AND AMLODIPINE BESYLATE AND THEIR PREPARATION - Google Patents

SOLID PHARMACEUTICAL FORMULATIONS OF RAMIPRIL AND AMLODIPINE BESYLATE AND THEIR PREPARATION

Info

Publication number
MA34130B1
MA34130B1 MA35197A MA35197A MA34130B1 MA 34130 B1 MA34130 B1 MA 34130B1 MA 35197 A MA35197 A MA 35197A MA 35197 A MA35197 A MA 35197A MA 34130 B1 MA34130 B1 MA 34130B1
Authority
MA
Morocco
Prior art keywords
ramipril
preparation
amlodipine besylate
pharmaceutical formulations
solid pharmaceutical
Prior art date
Application number
MA35197A
Other languages
French (fr)
Inventor
Nilesh Jaiswal
Praveen Khullar
Amol Kulkarni
Dilip Prajapati
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42786564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34130(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA34130B1 publication Critical patent/MA34130B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D11/00—Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of plastics material
    • B65D11/20—Details of walls made of plastics material

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques stables solides à dose fixée comprenant du ramipril, du bésylate d'amlodipine et des excipients pharmaceutiquement acceptables et sur leur préparation.The present invention relates to fixed dose solid stable pharmaceutical compositions comprising ramipril, amlodipine besylate and pharmaceutically acceptable excipients and to their preparation.

MA35197A 2010-02-24 2010-04-14 SOLID PHARMACEUTICAL FORMULATIONS OF RAMIPRIL AND AMLODIPINE BESYLATE AND THEIR PREPARATION MA34130B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN417DE2010 2010-02-24
PCT/IB2010/051616 WO2011104588A2 (en) 2010-02-24 2010-04-14 Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation

Publications (1)

Publication Number Publication Date
MA34130B1 true MA34130B1 (en) 2013-04-03

Family

ID=42786564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35197A MA34130B1 (en) 2010-02-24 2010-04-14 SOLID PHARMACEUTICAL FORMULATIONS OF RAMIPRIL AND AMLODIPINE BESYLATE AND THEIR PREPARATION

Country Status (28)

Country Link
US (1) US20130146496A1 (en)
EP (1) EP2538924B1 (en)
JP (1) JP5719385B2 (en)
KR (1) KR20120130761A (en)
CN (1) CN102781430B (en)
AR (1) AR080256A1 (en)
AU (1) AU2010346977A1 (en)
BR (1) BR112012021203A2 (en)
CA (1) CA2790817A1 (en)
CL (1) CL2012002341A1 (en)
CR (1) CR20120432A (en)
EA (1) EA201290817A1 (en)
EC (1) ECSP12012121A (en)
ES (1) ES2483154T3 (en)
GT (1) GT201200248A (en)
MA (1) MA34130B1 (en)
MX (1) MX2012009689A (en)
NI (1) NI201200136A (en)
PE (1) PE20130004A1 (en)
PL (1) PL2538924T3 (en)
SG (1) SG183449A1 (en)
SI (1) SI2538924T1 (en)
TN (1) TN2012000363A1 (en)
TW (1) TW201138767A (en)
UA (1) UA105285C2 (en)
UY (1) UY33243A (en)
WO (1) WO2011104588A2 (en)
ZA (1) ZA201205559B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814465B1 (en) 2012-02-17 2019-07-03 Egis Gyógyszergyár Zrt. Pharmaceutical formulation having improved stability
PL227900B1 (en) * 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Pharmaceutical composition comprising an ACE inhibitor and a calcium channel blocker, a method for its preparation and the dosage unit comprising the composition
CN104546773B (en) * 2015-01-30 2018-12-11 华润赛科药业有限责任公司 A kind of high stability amlodipine besylate tablets and preparation method thereof
WO2016207824A2 (en) * 2015-06-23 2016-12-29 Dr. Reddy's Laboratories Ltd A stable pharmaceutical composition comprising ramipril and/or amlodipine
EP3501502A1 (en) * 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633496A1 (en) 1986-10-02 1988-04-14 Hoechst Ag COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH CALCIUMANTAGONISTS AND THEIR USE IN MEDICINAL PRODUCTS
DK0804229T3 (en) 1995-03-16 2003-04-22 Pfizer Use of amlodipine, a salt thereof, or felodipine in combination with an ACE inhibitor for the manufacture of a medicament for the treatment of non-ischemic congestive heart failure
IL148127A0 (en) 1999-08-30 2002-09-12 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2005079772A2 (en) 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
HUP0401170A2 (en) * 2004-06-10 2006-09-28 Richter Gedeon Vegyeszet Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for
BRPI0517662A (en) * 2004-11-05 2008-10-14 King Pharmaceuticals Res & Dev coated stabilized ramipril particles, ramipril coating process, solid oral pharmaceutical composition, methods for preventing and treating cardiovascular disorders, and process for manufacturing a pharmaceutical composition
CN101272791A (en) * 2005-09-28 2008-09-24 特瓦制药工业有限公司 Stable composition of benzenesulfonic acid ammonia chlorine horizon and hydrochloric acid Benazepril
CA2620018A1 (en) * 2005-09-28 2007-04-12 Mali Kadosh Stable combinations of amlodipine besylate and benazepril hydrochloride
TWI399223B (en) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd Solid dosage form of olmesartan medoxomil and amlodipine
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor

Also Published As

Publication number Publication date
SG183449A1 (en) 2012-09-27
EP2538924B1 (en) 2014-05-21
AR080256A1 (en) 2012-03-21
TN2012000363A1 (en) 2014-01-30
CR20120432A (en) 2012-11-29
PL2538924T3 (en) 2014-10-31
KR20120130761A (en) 2012-12-03
JP5719385B2 (en) 2015-05-20
WO2011104588A3 (en) 2012-04-19
SI2538924T1 (en) 2014-09-30
MX2012009689A (en) 2012-09-12
CL2012002341A1 (en) 2012-11-30
BR112012021203A2 (en) 2016-05-17
CN102781430A (en) 2012-11-14
WO2011104588A2 (en) 2011-09-01
EP2538924A2 (en) 2013-01-02
TW201138767A (en) 2011-11-16
AU2010346977A1 (en) 2012-09-13
JP2013520485A (en) 2013-06-06
EA201290817A1 (en) 2013-01-30
NI201200136A (en) 2012-10-29
PE20130004A1 (en) 2013-02-01
GT201200248A (en) 2014-05-14
CN102781430B (en) 2015-09-09
ES2483154T3 (en) 2014-08-05
ECSP12012121A (en) 2012-09-28
UA105285C2 (en) 2014-04-25
US20130146496A1 (en) 2013-06-13
ZA201205559B (en) 2013-09-25
UY33243A (en) 2011-09-30
CA2790817A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
MA33463B1 (en) FIXED SOLID PHARMACEUTICAL DOSE COMPOSITIONS COMPRISING IRBESARTAN AND AMLODIPINE, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF
CY1115652T1 (en) DOSAGE FORM THAT CONTAINS TWO ACTIVE MEDICINAL MIXING INGREDIENTS IN DIFFERENT NATURAL FORMS
CY1119817T1 (en) SOLID DOSAGE UNIT DISTRIBUTED IN THE MOUTH CONTAINING OSTETROL INGREDIENT
MX2009007784A (en) Compositions of stable tiacumicins.
WO2015120110A3 (en) Novel pharmaceutical formulations
EA201490477A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PROPYLENE GLYCOL-HYDRATE DAPAGLYFLOSINE
NO20043367L (en) Oral pharmaceutical preparation
UA110012C2 (en) MEDICINAL FORM FOR ORAL APPLICATION CONTAINING LICARBAZEPINE ACETATE
MX2013014788A (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]am ino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids.
EA201171109A1 (en) NEW COMPOSITION OF THE DELAYED RELEASE OF COMPOUNDS SELECTED FROM THE CLASS OF MINORALEXANTS OF CENTRAL ACTION
EA201290734A1 (en) RIFAXIMIN IN THE FORM OF POWDER, THE METHOD OF ITS PRODUCTION AND THE COMPOSITION OF CONTROLLED LIBERATION CONTAINING RIFAXIMIN INDICATED, USEFUL FOR ACHIEVING A LONG-TERM EFFECT
UA116334C2 (en) SOLID FORMS OF BENDAMUSTINE DOSAGE
ATE487720T1 (en) 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS
MA34130B1 (en) SOLID PHARMACEUTICAL FORMULATIONS OF RAMIPRIL AND AMLODIPINE BESYLATE AND THEIR PREPARATION
PH12015500823A1 (en) Modified release formulations for oprozomib
EA201500513A1 (en) SOMICRONIZATION PRODUCT, INCLUDING ULETRIDAL ACETATE
EA201170583A1 (en) NEW COMPOSITION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTEMIA
ATE460934T1 (en) PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN
MX2017005163A (en) Onapristone extended-release compositions and methods.
TR201803451T4 (en) OLMESARTAN FORMULATIONS.
RU2012136190A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT
IN2014DN07898A (en)
MA38093A1 (en) Modified release formulations for oprozomib
IN2013MU02286A (en)